ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L09

Impact on Access to Methotrexate in the Post-Roe Era

Kristin Wipfler1, Adam Cornish1, Rebecca Schumacher2, Yomei Shaw3, Patricia Katz4 and Kaleb Michaud5, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 3FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, 4UCSF, San Rafael, CA, 5University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: Access to care, Disease-Modifying Antirheumatic Drugs (Dmards), Disparities, Health policy, Late-Breaking 2022, registry

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: (L07–L17) Late-Breaking Abstract Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can be used to treat miscarriage and ectopic pregnancy. Following the US Supreme Court’s June 24 decision to overturn Roe v Wade, many states have enacted laws that ban or restrict abortion. As a result, some patients have reported difficulty filling their methotrexate prescriptions to treat their arthritis, but the scope and severity of this issue is unknown. The objective of this study was to assess the impact of this decision on individuals with rheumatic diseases and their access to care.

Methods: Data were provided by adults participating in FORWARD, The National Databank for Rheumatic Diseases who completed a survey about post-Roe medication access. Participants were provided a description of the Supreme Court decision and were asked if they experienced any issues accessing medication since June 24 (response options are shown in Figure 1B). Respondents were also asked if they had attempted to refill methotrexate since June 24 and what medication was affected if they experienced an issue. Responses were linked to participants’ most recent semiannual questionnaire for demographics, primary diagnosis, and patient-reported outcomes. Participants’ states of residence were categorized by abortion legality status.

Results: Of 1,706 respondents, 396 reported attempting to fill a methotrexate prescription since June 24. Of those, 23 (6%) reported experiencing a barrier to methotrexate access. One additional respondent reported restricted access to hydroxychloroquine (Figure 1A). Descriptive statistics are presented in Table 1. Most (63%) respondents who reported an issue indicated they experienced a delay in prescription refilling by their pharmacy (Figure 1B). Of the 24 who experienced a problem, 11 responded to a request for follow up to provide additional information. Of those, 5 experienced barriers that were overtly a result of the Supreme Court’s decision (respondents reported being told directly that the issue was due to pregnancy risk/concerns related to abortion) and 6 experienced barriers suggestive of being a consequence of the decision (respondents reported unexpected delays/refusals without being given a clear explanation or reasoning; Figure 1C).

Conclusion: Within two months of the Supreme Court’s overturn of Roe v Wade, 1 in 17 individuals who tried to fill a methotrexate prescription experienced an unexpected barrier. Respondents to this survey were predominantly white, older than child-bearing age, educated, and insured; the impact in higher risk populations may be more severe. Most issues experienced were delays by pharmacies seeking to confirm the purpose of the prescription with the patient’s health care provider. To reduce or avoid these delays, we recommend that health care providers prescribing methotrexate or other medications that are teratogenic or abortifacient include the patient’s diagnosis on the prescription.

Supporting image 1

Supporting image 2


Disclosures: K. Wipfler, None; A. Cornish, None; R. Schumacher, None; Y. Shaw, None; P. Katz, None; K. Michaud, None.

To cite this abstract in AMA style:

Wipfler K, Cornish A, Schumacher R, Shaw Y, Katz P, Michaud K. Impact on Access to Methotrexate in the Post-Roe Era [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-on-access-to-methotrexate-in-the-post-roe-era/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-on-access-to-methotrexate-in-the-post-roe-era/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology